Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
Could the rare-disease-focused biotech Sarepta Therapeutics (NASDAQ: SRPT) one day become a towering, innovative, and profitable growth business, as biopharma Vertex Pharmaceuticals (NASDAQ: VRTX) is today? It's more likely than it might seem at first glance. Here's why.
Vertex Pharmaceuticals has been a solid investment for a few reasons. First, it's the only company that sells therapies treating the root causes of cystic fibrosis (CF), a rare hereditary lung disease. Rather than settling for producing one drug to serve the CF market, Vertex has several, some of which are repackaged combinations of its other medicines.
Its pipeline is packed with more therapies for CF, and it also features programs targeting other rare diseases. The appeal of such an approach is that it enables Vertex to use its institutional acumen and close relationships with the community of CF patients as a competitive advantage. And it's led that market for many years already, generating billions in earnings along the way, and $3.3 billion in net income in 2022 alone.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
Vertex Pharmaceuticals Inc. ist ein klarer Community-Favorit mit mehr Buy- als Sell-Einschätzungen.
Trotz eines Kursziels von 440 €, das unter 452.85 € liegt, ergibt sich für Vertex Pharmaceuticals Inc. ein negatives Potenzial von -2.84%.
